Physician profile
Varun Gupta
NPI 1669433306
$3,290.10
in general payments reported to CMS, 2019-2025
19 companies · $1,959 in 2025
The $1,959 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $18.11 · 2023: $777 · 2024: $103 · 2025: $1,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,275 · Food and Beverage: $1,143 · Travel and Lodging: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,275.00 |
| Food and Beverage | $1,143.26 |
| Travel and Lodging | $420.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $1,815.69 | 2025 | Qinlock |
| Medtronic, INC. | $301.29 | 2023-2024 | Synchromedii, Osteocool Rf Ablation System |
| Astellas Pharma US INC | $245.25 | 2019-2023 | Padcev, Xospata |
| Sirtex Medical INC | $143.00 | 2025 | Sir-Spheres Microspheres |
| Pfizer INC. | $122.82 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $120.73 | 2019 | |
| Lilly USA, LLC | $112.69 | 2019-2023 | Jaypirca, Verzenio |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Incyte Corporation | $89.82 | 2023 | Jakafi |
| Daiichi Sankyo INC. | $51.44 | 2023 | Enhertu |
| Seagen INC. | $38.31 | 2023 | Padcev, Tukysa |
| Merck Sharp & Dohme LLC | $27.92 | 2023 | Lynparza, Keytruda |
| Eisai INC. | $24.35 | 2023 | |
| Janssen Biotech, INC. | $22.82 | 2019 | |
| Celgene Corporation | $22.13 | 2024 | Reblozyl |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17.46 | 2023 | |
| Sobi, INC | $17.41 | 2023 | |
| Genzyme Corporation | $16.98 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.